fMRI during performance of a cognitive control task. Randomization of treatment order was performed without stratification, with a computer algorithm by a research pharmacist, who also packaged active medication and placebo in identical-appearing capsules for administration, and was otherwise uninvolved in the study. Eleven subjects completed the active drug testing day first, and ten subjects completed the placebo day first. In the subgroup off-ceiling for performance, 6 performed the placebo day first, and 5 performed the drug day first. All investigators remained blind to treatment order for individual subjects until all data was acquired for that subject, and treatment order information was then necessary to sort data for inferential testing. All subjects received the dose of either active drug or placebo in the morning (separated by at least three days to ensure adequate drug wash-out), with the immediate measurement thereafter of baseline blood pressure and heart rate, and completion of the baseline Profile of Mood States self-report questionnaire (POMS-State version). Immediately prior to MRI scanning, blood pressure and heart rate measurement was repeated; echo-planar imaging was initiated at an average elapsed time 3.6 ± 0.2 hours post-dose, within the time window of reported average peak plasma levels of modafinil (S1). After scanning, all subjects completed the POMS again. No subjects reported any adverse subjective or physical symptoms during study procedures.
Cognitive Paradigm.
The Preparing to Overcome Prepotency (POP) task was presented using EPrime software, and requires cognitive control to overcome a prepotent stimulus-response mapping (Supplemental Fig. 1) . A visual cue (Red or Green color patches, 500 ms duration) in the center of the visual field instructs a stimulus-response (S-R) mapping to the probe, which occurs after a delay. The probe is a leftward or rightward-pointing arrow, which occur with equal frequency, presented in the center of the visual field and onset at 8 seconds after cue onset, and also 500 ms in duration. The direction of the arrow probe is randomized to preclude the preparation of specific motor responses in the cue-probe delay period. The response demand is prepotent for Green-cued trials (i.e., the correct response is a left button-press for leftward arrows, and right for right), and is nonprepotent for Red-cued trials (i.e. left button-press for rightward arrows, and vice versa).
The period from probe onset to cue onset of the successive trial is 12 seconds. During both cue-probe delay and probe-cue interval, subjects are instructed to fixate visually on a crosshair presented in the center of the visual field. Four blocks with 20 trials each were performed, with randomized order of cues, 70% of which were comprised of prepotent (Green-cued) S-R mappings, and each block lasting 6 minutes 40 seconds. Subjects were instructed to "go as fast as you can without making mistakes." High-control demands (Red-cued trials) are associated with decrements (costs) in response accuracy and speed, and robust activity of the dorsolateral, rostral and medial PFC during preparatory cueprobe delay periods, and medial PFC (anterior cingulate and supplemental motor area), premotor cortex and parietal cortex during the experience of response conflict after probe onset (S2,S 3).
fMRI Acquisition and Pre-processing. Event-related fMRI was conducted on a 3 Tesla Siemens Trio MRI system with a Siemens 8 channel phased array coil. Measurement of Blood Oxygen Level-Dependent (BOLD) contrast was conducted during single-shot, echo-planar imaging (EPI), using a T2*-weighted sequence, and whole-brain coverage. The parameters of the EPI sequence were TR 2000 ms, TE 30 ms, flip angle 90°, FOV 220 x 220 mm, with 36 contiguous slices in the axial oblique plane with voxel size 3.4 mm isotropic. Pre-processing was performed using SPM5. The first four images (preceding onset of trial one of block one) were discarded to allow for stabilization of the scanner signal. The remaining images were realigned (motion-corrected) to the first retained image in the first block, then adjusted for acquisition time (slice timing correction), then subject to spatial normalization directly to the EPI template from the SPM5 library, via 6-parameter rigidbody affine transformation. Images were then resliced to 2x2x2 and spatially smoothed with an 8 mm, full-width-at-half-maximum Gaussian kernel. At this point, Drug and Placebo day scans were concatenated for the purpose of modeling of the signal and inferential testing.
Univariate inferential testing of voxel-wise drug effects on neural activity.
For the Univariate analysis, derivation of the signal proceeded with the use of the General Linear Model. Regressors were established for Drug_RedCues, Drug_GreenCues, Placebo_RedCues, and Placebo_GreenCues. We also included a regressor for errors, to account for this event-related signal change, but did not include errors in the inferential testing, as they were too rare for reliable analysis (see task performance results below).
A canonical (double-gaussian) hemodynamic response function was convolved with the BOLD time series, with regressors placed at cue and probe onset. We also established the temporal derivative of the HRF as a regressor, paired with each of the experimental condition regressors, to account for temporal variation in the latency of the event-related response. A 0.0125 Hz high-pass filter was used, a first-order autoregressive function to account for serial autocorrelations, and global normalization to account for global differences in signal value across scans. After signal estimation, linear contrasts were defined at the single-subject level (see below), and then relevant contrast maps from individual subjects (containing voxel-wise parameter estimates for a given contrast) were entered into the group-level analysis for inferential testing. In order to define topographic masks for use in the contrasts of interest, the first two authors drew an anatomic mask of the pons, defined on the T1 152 MNI template in the SPM5 library, using ITK-SNAP software. In order to mask the rest of the brain during inferential testing of Drug effects throughout the cognitive control network, we identified a "univariate mask" as cognitive control-related brain areas of activation, defined as the union of (Drug_RedCue minus Drug_GreenCue) with (Placebo_RedCue minus Placebo_GreenCue), each at a voxelwise threshold of p<.05 uncorrected. The task-independent Drug effect was then tested with the contrast defined as (Drug_RedCue + Drug_GreenCue) > (Placebo_RedCue + Placebo_GreenCue). We hypothesized that in these univariate analyses, significant Drug effects would be manifest as deactivations in the pons. For Drug effects on task-related activity, the contrast was established as (Drug_RedCue minus Drug_GreenCue) > (Placebo_RedCue minus Placebo_GreenCue). In this contrast, we hypothesized that the Drug would serve to positively enhance pontine activity, since despite a task-independent effect of Drug manifest as deactivation, the drug would augment the positive difference in activity related to cognitive control demands (i.e. Red Cue over Green Cue-related activity). This contrast also tested the hypothesis that elsewhere in the cognitive control network, the drug would be associated with a significantly greater enhancement of control-related BOLD signal change, compared to placebo. For these and all other voxelwise tests indicated below, the threshold for statistical significance was set at p < .05, corrected for multiple comparisons using the False Discovery Rate method.
Bivariate analysis of trial-by-trial LC-cognitive control network correlations.
We also conducted a bivariate analysis in order to test the hypothesis that, under (druginduced) conditions which reduce tonic and promote phasic LC activity, the degree of trial-bytrial coupling of LC deactivation with PFC terminal field activation would increase. In other words, we predicted that the negative correlation between LC activity and PFC activity would become stronger, i.e., significantly more negative. We utilized the beta-series correlation method of (S4) to derive trial-by-trial parameter estimates in order to correlate time series between the LC and PFC. This method uses HRF-convolved, unique trial-specific regressors to model responses to each event (using the General Linear Model) at each voxel. The resulting trial-specific β values (parameter estimates) are sorted according to the regressor type with which they are associated, to form a β series for each of the four drug-by-cue conditions. The LC "seed region" was defined as the brainstem cluster with significant deactivation in the univariate task-independent effect of Drug (see Table S1 and Fig. 2) . For each subject then, coupling between brain regions was measured by computing the bivariate Pearson correlations between the time series of mean β value across all voxels contained in the seed region, and the β from each remaining voxel throughout the brain, independent of other remaining voxels. In this manner, each voxel outside the seed region is assigned Pearson correlation coefficients for each of the experimental conditions, as voxel-wise measures of its association of event-related signal with that of the seed under different experimental conditions. Correlations are performed in Matlab (with scripts developed for this analysis) separately on data from each individual subject, and transformed to Z scores for inferential testing at the group level.
The beta series method has a number of advantages in the context of the present study. It allows connectivity between brain regions to be distinguished by task phase, because each phase of each trial is modeled with a unique regressor. This is critical to determine brain region interactions associated with distinct cognitive subcomponent processes in complex tasks, such as the cue-related processing which is emphasized here. It is also particularly suitable to slow event-related designs such as that used here (see S4 for discussion). In addition, because a GLM-based method is used to derive the critical measure for inferential testing, just as it is in the univariate analysis, this common procedure facilitates the direct, qualitative comparison of univariate and bivariate results. Furthermore, because our hypotheses all stem from actions arising at a single brain region (LC), including LC relationships with the distributed cognitive control network, the use of a "seed" in order to evaluate drug effects on LC-NE modulation of widespread cortical/subcortical terminal fields allows for straightforward interpretations of resulting data. It is important to acknowledge that this method cannot allow for inferences regarding directional relationships between LC and terminal fields.
Inferential testing proceeds in a manner completely analogous to that for the univariate data, yielding test statistics, at each voxel, of the magnitude of coupling of LC seed activity with voxel-wise terminal field activity. As before, the threshold for statistical significance was set at p < .05 corrected for multiple comparisons using the False Discovery Rate. Due to the risk of making spurious inferences from the evaluation of linear contrasts of negative correlations, with hypotheses that drug effects increase the negativity of correlations, we constrained the group-level, voxel-wise analyses of the bivariate data in the following manner. We reasoned that we were not only interested in interrogating those brain areas that are active with cognitive control demands, but also that smaller values would unambiguously represent stronger negative correlations only if the correlations on Drug were proven to be negative to begin with. Therefore, we established the mask as the conjunction of the univariate cognitive control mask (defined above) with areas where the correlations on Drug were less than zero, i.e., significant areas in the Drug < Null contrast, at p < .05 uncorrected. The task-independent effect of Drug on these Beta series correlations was tested, using this mask, via the contrast (Drug_RedCue + Drug_GreenCue) < (Placebo_RedCue + Placebo_GreenCue). For task-related drug effects, we hypothesized that the drug would drive control-related negative coupling to a greater degree than placebo. That is, we hypothesized that the difference in correlations observed as (Drug_RedCue minus Drug_GreenCue) would be significantly more negative (smaller) than the difference in correlations observed as (Placebo_RedCue minus Placebo_GreenCue). We then tested this hypothesis with the masked contrast (Drug_RedCue minus Drug_GreenCue) < (Placebo_RedCue minus Placebo_GreenCue).
Supplemental Results
Effects of Drug on vital signs and self-reported subjective state.
No significant effects of modafinil were observed on vital signs. Change scores from pretreatment to post-treatment were (Drug versus Placebo): systolic blood pressure, 7 ± 14 vs. 3 ± 16; diastolic blood pressure, 2 ± 12 vs. 0.4 ± 10; heart rate, -3 ± 6 vs. Modafinil increased task-related activity in a cortical-thalamo-striatal network (Fig. 2 and Table S1 ). PFC areas frequently implicated in control processes included midline frontal and bilateral PFC areas such as the cingulate cortex, premotor and primary motor cortex, and smaller, more rostral and ventral areas in the middle frontal gyrus and right orbitofrontal gyrus. We also found increased task-related activity on modafinil in a right hemisphere network, including a midbrain area that includes the substantia nigra; the putamen/caudate, pulvinar, and superior temporal gyrus extending into the inferior parietal lobule.
Effects of Drug on Connectivity of LC with the Cognitive Control Network.
Brain regions which support cognitive control exhibited increased coupling with the LC as a task-independent drug effect (Fig 3 and Table S2 ). These areas included bilateral mid-DLPFC and rostral PFC, right ventrolateral PFC, bilateral anterior cingulate cortex extending into supplemental motor area, and more posteriorly, right superior parietal lobule and bilateral precuneus.
Effects of Drug on cognitive control task performance. 
